[go: up one dir, main page]

MX2019007615A - Imagenología de celulas tumorales e inmunitarias basadas en expresion de pd-l1. - Google Patents

Imagenología de celulas tumorales e inmunitarias basadas en expresion de pd-l1.

Info

Publication number
MX2019007615A
MX2019007615A MX2019007615A MX2019007615A MX2019007615A MX 2019007615 A MX2019007615 A MX 2019007615A MX 2019007615 A MX2019007615 A MX 2019007615A MX 2019007615 A MX2019007615 A MX 2019007615A MX 2019007615 A MX2019007615 A MX 2019007615A
Authority
MX
Mexico
Prior art keywords
tumor
expression
immune cell
cell imaging
imaging based
Prior art date
Application number
MX2019007615A
Other languages
English (en)
Inventor
G Pomper Martin
Nimmagadda Sridhar
Chatterjee Samit
G Lesniak Wojciech
Kumar Dhiraj
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2019007615A publication Critical patent/MX2019007615A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/225—Microparticles, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acoustics & Sound (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La materia actualmente descrita proporciona composiciones, equipos, y métodos que comprenden agentes trazadores que pueden detectar el Ligado 1 de Muerte Programada (PD-L1). Los agentes trazadores actualmente descritos se pueden usar para detectar enfermedades y trastornos, tal como cáncer, infección, e inflamación, en un sujeto.
MX2019007615A 2016-12-23 2017-12-21 Imagenología de celulas tumorales e inmunitarias basadas en expresion de pd-l1. MX2019007615A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438575P 2016-12-23 2016-12-23
US201762519534P 2017-06-14 2017-06-14
PCT/US2017/068025 WO2018119313A1 (en) 2016-12-23 2017-12-21 Tumor and immune cell imaging based on pd-l1 expression

Publications (1)

Publication Number Publication Date
MX2019007615A true MX2019007615A (es) 2019-11-05

Family

ID=62627749

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007615A MX2019007615A (es) 2016-12-23 2017-12-21 Imagenología de celulas tumorales e inmunitarias basadas en expresion de pd-l1.

Country Status (11)

Country Link
US (1) US11607466B2 (es)
EP (1) EP3558395A4 (es)
JP (3) JP7784103B2 (es)
KR (2) KR20240023665A (es)
CN (1) CN110366432A (es)
AU (1) AU2017382282B9 (es)
BR (1) BR112019012986A2 (es)
CA (1) CA3048229A1 (es)
IL (1) IL267572B2 (es)
MX (1) MX2019007615A (es)
WO (1) WO2018119313A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN109512798B (zh) * 2019-01-15 2022-05-13 南京从一医药科技有限公司 一种用于抗肿瘤免疫治疗的药物组合物纳米体系
CN111662270A (zh) * 2019-03-05 2020-09-15 中国医学科学院药物研究所 碘同位素标记苄苯醚衍生物、及其制法和药物组合物与用途
CN110898234B (zh) * 2019-12-25 2020-12-22 河南大学 一种二维铋纳米复合材料及其制备方法和应用
US11613755B2 (en) 2019-12-31 2023-03-28 Industrial Technology Research Institute Nucleic acid-drug complex and use thereof
CN112067586B (zh) * 2020-06-24 2021-08-03 江南大学 一种基于荧光淬灭拉曼增强的前列腺特异性抗原双信号光谱分析方法
EP4192524A4 (en) * 2020-08-07 2024-12-04 The Johns Hopkins University IMAGING AND TARGETING PROGRAMMED DEATH LIGAND 1 (PD-LI) EXPRESSION
DE102020130954A1 (de) 2020-11-23 2022-05-25 Universität Duisburg-Essen Markierungspartikel für Raman-Streuung und/oder Fluoreszenz-Strahlung
CN114853851B (zh) * 2021-02-04 2023-08-15 南方医科大学南方医院 靶向pd-l1多肽探针及其在制备pet显像剂中的应用
CN113341023B (zh) * 2021-06-30 2022-12-23 大连医科大学附属第一医院 一种基于液质联用的血清二氨基庚二酸的检测试剂盒及检测方法与应用
US20250135047A1 (en) * 2021-08-06 2025-05-01 The Johns Hopkins University Improved aluminum fluoride radiosynthesis of [18f]dk222
CN115364247A (zh) * 2021-09-15 2022-11-22 中国人民解放军海军军医大学第一附属医院 一种靶向显影剂、制备方法及其应用
CN114010655B (zh) * 2021-11-02 2023-02-03 安徽医科大学第一附属医院 一种识别和降解前列腺癌细胞表面的pd-l1的金纳米星及其制备方法和应用
CN114569745A (zh) * 2022-03-18 2022-06-03 哈尔滨医科大学 一种靶向pd-l1的多肽pet分子成像探针及其制备方法与应用
WO2025061971A1 (en) * 2023-09-20 2025-03-27 Trimt Gmbh Functionalized peptides for in-vivo addressing of pd-l1 expression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1603598T1 (sl) * 2003-03-19 2009-02-28 Universitaetsspital Basel Radiooznačeni konjugati na osnovi substance P innjihove uporabe
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
WO2012074840A2 (en) * 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
WO2013032839A2 (en) * 2011-09-02 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University Raman imaging devices and methods of moleclar imaging
WO2014043606A1 (en) * 2012-09-14 2014-03-20 The Johns Hopkins University Bacteria-specific labeled substrtates as imaging biomarkers to diagnose, locate, and monitor infections
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
EP3191113B1 (en) * 2014-09-11 2019-11-06 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-l1 protein/protein interactions
CN114591420A (zh) * 2014-11-25 2022-06-07 百时美施贵宝公司 用于成像的新型pd-l1结合多肽
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
EA038019B1 (ru) 2016-05-19 2021-06-23 Бристол-Маерс Сквибб Компани Иммуномодуляторы для пэт-визуализации
CN107869033B (zh) * 2016-09-26 2020-10-02 青岛胶南海尔洗衣机有限公司 一种干衣机用正反转风扇及干衣机

Also Published As

Publication number Publication date
KR20190102018A (ko) 2019-09-02
CN110366432A (zh) 2019-10-22
US20190314531A1 (en) 2019-10-17
AU2017382282A1 (en) 2019-07-11
IL267572B1 (en) 2024-10-01
AU2017382282B9 (en) 2025-02-13
JP2025118743A (ja) 2025-08-13
JP7784103B2 (ja) 2025-12-11
JP7680759B2 (ja) 2025-05-21
JP2023052071A (ja) 2023-04-11
KR102662725B1 (ko) 2024-04-30
US11607466B2 (en) 2023-03-21
WO2018119313A1 (en) 2018-06-28
JP2020514278A (ja) 2020-05-21
KR20240023665A (ko) 2024-02-22
CA3048229A1 (en) 2018-06-28
AU2017382282B2 (en) 2025-01-30
BR112019012986A2 (pt) 2019-12-03
EP3558395A1 (en) 2019-10-30
IL267572B2 (en) 2025-02-01
EP3558395A4 (en) 2020-08-12
IL267572A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2019007615A (es) Imagenología de celulas tumorales e inmunitarias basadas en expresion de pd-l1.
WO2015116868A3 (en) Molecular profiling of immune modulators
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
PH12017500803A1 (en) Anti-pd-1 antibodies
GEAP202415222A (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
PH12016500840A1 (en) Methods of using interleukin-10 for treating diseases and disorders
SG11201900171QA (en) Antibody for anti-claudin 18a2 and use thereof
TW201713698A (en) PD-1 antibodies
MX2022007522A (es) Anticuerpos anti-cd27.
EA201991555A1 (ru) Композиции и способы усиления или увеличения продукции ifn i типа
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
EP4527922A3 (en) Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
MY196173A (en) Cot Modulators And Methods Of Use Thereof
MD4733B1 (ro) Anticorpi anti-TIGIT
MX2023012451A (es) Composiciones para usarse en el tratamiento de una enfermedad autoinmune y cancer.
SA518391121B1 (ar) 18f مثبطات موسومة بواسطة (psma) في مستضد الغشاء الخاص بالبروستاتا واستخدامها كعوامل تصوير تشخيصي لحالات سرطان البروستاتا
Sengupta et al. Berberine and S allyl cysteine mediated amelioration of DEN+ CCl4 induced hepatocarcinoma
MX2023012628A (es) Metodos y composiciones para deteccion y diagnostico de enfermedades renales y enfermedades periodontales.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
WO2020131586A3 (en) Methods for identifying neoantigens
WO2018009507A8 (en) COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE
MX392199B (es) Composiciones farmaceuticas para terapia de combinacion
WO2017132555A8 (en) Alk polypeptides and methods of use thereof
MX385304B (es) Nuevos complejos metálicos de nocardamina y su uso en composiciones farmacéuticas.